Gadeta (Netherlands) has raised €7M in a series A round, which will fuel the clinical development of its novel TCR platform, starting with a leukemia cell therapy trial.

gadeta_gammadelta_tcr_cancer_immunoGadeta is a spin-out of immuno-oncology research at the University Medical Center Utrecht (UMC Utrecht). It was founded in 2015 by the researchers and Utrecht Holdings, the technology transfer arm of Utrecht University, and received seed funding from Medicxi Ventures – the recently rebranded Index Ventures life sciences VC.

Gadeta has now raised €7M in a series A round, and snatched a new investor – Baxalta Ventures, which will have one of its partners joining the supervisory board.

Baxalta Ventures is the investment arm of Baxalta in Illinois (US) – a Biopharma which is itself a spin-out of Baxter, spun from its portfolio in hematology, immunology and oncology.

Baxalta’s VC side business is also focusing on the same therapeutic areas. Its prior investments in European Biotech included Covagen (Switzerland), which is also developing immunotherapies and was acquired by Janssen in 2014.


Current investors of Gadeta.

But what is Gadeta developing exactly?

Its immuno-oncology strategy is based on the work of Jürgen Kuball (one of the founders), who researched γδ T-cells – a small subgroup of T-cells that express a unique T-cell receptor  (TCRs). Targeting TCRs has already yielded promising results for Adaptimmune (UK) and Immunocore (also in the UK).

Gadeta has therefore developed a new technology platform, named Combinatorial T-Cell Receptor Exchange (CTE), to create optimised TCRs with enhanced anti-cancer reactivity.

These next-generation TCRs can sense metabolic changes in cancer cells, so it is expected that they show high selectivity (no damage to healthy tissue), as well as work with both blood cancers and solid tumours.


Gadeta’s concept to develop novel cancer immunotherapies (Source: Gadeta)

Gadeta plans to use the mevalonate pathway (an important pathway that produces components of the cellular membrane) as a metabolic cancer target.  Dysregulation of this pathway is common in many cancers and leads to increases of a specific antigen in the cell’s membrane (phospoantigens or IPP) – which can be sensed by the TCRs.

With fresh money in its pockets, Gadeta expects to start a Phase I/IIa clinical trial of its lead program in acute myeloid leukemia (AML) in early 2017, and  a second clinical trial in solid tumors later in the year.

This combination of the CAR-T/TCR with metabolic cancer targeting is an interesting strategy – and investors seem to agree.

Featured image credit: Cancer Cells © Jezper (Dreamstime ID28816229)
Previous post

Top 10 Biotech jobs and internships in Europe you MUST see this week! (Medpace, Sanofi, Boehringer Ingelheim)

Next post

German Biotech targets China for Lung Cancer Liquid Biopsies